#310 - Can We Measure Aging Well Enough to Treat It? | Dr. Nir Barzilai & Mike Haney

Aging science has gotten much better at describing who appears to be aging faster or slower. What medicine still lacks is a reliable feedback loop: a way to tell whether something we do is actually changing the biology that drives age-related disease.

Dr. Nir Barzilai argues that solving that measurement problem could turn geroscience from an interesting field of research into something doctors can actually use: measure where you are, intervene, measure again, and learn what works.

Free course: Improve your metabolic health

Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠

What We Cover:

What centenarians reveal about living longer and spending less time sick
Why changing one hallmark of aging can affect several others
How TAME was designed to test metformin as an anti-aging drug and to convince the FDA to treat aging itself as an endpoint—and why it failed to get off the ground
Why metformin, SGLT2 inhibitors, GLP-1 agonists, and some osteoporosis drugs are being studied as potential gerotherapeutics, or anti-aging drugs
How FAST is searching existing clinical trials for biomarkers that change when an intervention affects aging biology
Whether aging needs continuous monitoring or can be meaningfully tracked a few times a year

🎙️ About the Guest:

Dr. Nir Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and a professor of medicine and genetics at Albert Einstein College of Medicine, where he directs the Institute for Geroscience.

📍What Dr. Nil Barzilai & Mike Haney discussed:

05:10 - Aging is a condition, not just a label
05:59 - Why aging is what drives disease
08:19 - Should we call aging a disease?
10:20 - Why the species may have a ceiling around 115
14:34 - Why changing one hallmark of aging changes the others
23:08 - Metformin was anti-aging before it was a diabetes drug
31:55 - Centenarians live longer and spend less time sick
40:12 - How TAME tried to make aging an FDA endpoint
48:17 - Metformin, SGLT2s, GLP-1s, and osteoporosis drugs as gerotherapeutics
52:26 - FAST: finding biomarkers that actually change with treatment
56:49 - Whether aging needs continuous monitoring, or a few checks a year
1:01:16 - Where behavior still fits once we have anti-aging drugs

🔗 Helpful Links:

Hallmarks of Aging: An Expanding Universe (Cell, 2023) Paper
Compression of Morbidity Is Observed Across Cohorts with Exceptional Longevity (JAGS, 2016) Paper
Metformin as a Tool to Target Aging (Cell Metabolism, 2016) Paper
Geroscience-Guided Repurposing of FDA-Approved Drugs to Target Aging (Aging Cell, 2022) Paper
Biomarkers of Aging for the Identification and Evaluation of Longevity Interventions (Cell, 2023) Paper
FAST: Finding Aging Biomarkers by Searching Existing Trials FAST Initiative
ARPA-H PROSPR / FAST award ARPA-H FAST project

Watch the conversation: https://youtu.be/HbeGjwCw6vk

Find us on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/levelshealth?sub_confirmation=1⁠⁠⁠⁠⁠⁠⁠

📲 Connect:

Connect with Dr. Nil Barzilai on X: https://x.com/NirBarzilaiMD

👋 Who we are:

Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.

Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(317)

#318 - How Sleep Changes What and How Much You Eat | Dr. Marie-Pierre St-Onge & Mike Haney

Sleep and diet don’t operate independently. Controlled studies suggest that when people sleep less, they tend to eat more, move less, and gradually gain weight. The relationship also appears to run in...

5 Nov 53min

#317 - What It Takes to Build Medical AI Doctors Will Trust | Dr. Suchi Saria & Mike Haney

Medical AI is full of impressive models that work on retrospective datasets. The much harder problem is turning one into a tool that can operate continuously inside a hospital, earn clinicians’ trust,...

29 Okt 1h 1min

#316 - What Should You Actually Do About High Cholesterol? | Dr. Seth Martin & Mike Haney

Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atheros...

22 Okt 1h 8min

#315 - Can We Treat Disease Through the Nervous System? | Dr. Kevin Tracey & Mike Haney

Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know ...

15 Okt 1h 21min

#314 - How to Make Health Decisions When the Science Is Unclear | Dr. Anupam Jena & Mike Haney

Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may no...

8 Okt 57min

#313 - What Happens When We Start Imaging Healthy People? | Dr. Daniel Durand & Mike Haney

Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body...

1 Okt 1h 25min

#312 - Is Moderate Drinking Actually Healthy? | Dr. Tim Naimi & Mike Haney

Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan.Dr. Tim Naimi ...

24 Sep 53min

#311 - Can Your Blood Predict Your Future Health? | Dr. Tony Wyss-Coray & Mike Haney

From a single blood sample, new proteomic tools can now measure thousands of proteins at once. Dr. Tony Wyss-Coray’s lab is using that flood of data, together with machine learning, to build a much hi...

17 Sep 1h